ecancermedicalscience最新文献_第5页

Survival rate of cervical cancer: a five year review at a Major Teaching Hospital in Ghana, West Africa 宫颈癌存活率：西非加纳一家主要教学医院的五年回顾

ecancermedicalscience Pub Date : 2024-02-01 DOI: 10.3332/ecancer.2024.1663

Joseph Daniels, Kwesi Asante, Judith Naa Odey Tackie, K. A. Kyei

{"title":"Survival rate of cervical cancer: a five year review at a Major Teaching Hospital in Ghana, West Africa","authors":"Joseph Daniels, Kwesi Asante, Judith Naa Odey Tackie, K. A. Kyei","doi":"10.3332/ecancer.2024.1663","DOIUrl":"https://doi.org/10.3332/ecancer.2024.1663","url":null,"abstract":"Cervical cancer (CC) is one of the leading causes of cancer-related deaths among females in Ghana. Despite the magnitude of the public health challenge posed by CC in Ghana, survival data as well as reported incidence and mortality rates are primarily based on studies conducted in the capital city of the country. Even though age at diagnosis is known to affect the overall survival of CC patients, the role of this factor in the prognosis of CC patients in Ghana has not been sufficiently explored. The aim of this study was to determine the 5-year survival rate of Ghanaian woman treated for CC at a large tertiary healthcare facility in Ghana. This research was a single-institution-based quantitative retrospective cohort study conducted among patients with histopathologically confirmed CC. Clinical and socio-demographic data were retrieved from patients’ medical records. Data analysis was done using the Statistical Package for the Social Sciences software version 23. Kaplan Meier curves were used to present the survival rates and median survival time. The peak age at diagnosis was between 45 and 80 years with the modal age group of patients between 75 and 80 years. The mean age at diagnosis was 63.3 ± 15.7 years ranging from 27 to 104 years. The overall survival rates at 1, 3 and 5 years were 76.5%, 51.5% and 32.4%, respectively. The median survival time was 65.8 months. Age < 50 years was associated with higher survival estimates than age >50 years. The 5-year over-all survival rate of CC patients reported in this study (32.4%) is relatively low compared with countries in the developed world but like previous reports at other healthcare facilities in Ghana as well as in other underdeveloped countries.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"46 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139814220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical usefulness of the patient-generated subjective global assessment short form© for nutritional screening in patients with head and neck cancer: a multicentric study 患者自制主观全面评估简表© 在头颈癌患者营养筛查中的临床实用性：一项多中心研究

ecancermedicalscience Pub Date : 2024-02-01 DOI: 10.3332/ecancer.2024.1662

Mariana Duarte Azevedo, N. B. de Pinho, Patricia de Carvalho Padilha, Livia Costa de Oliveira, Wilza Arantes Ferreira Peres

{"title":"Clinical usefulness of the patient-generated subjective global assessment short form© for nutritional screening in patients with head and neck cancer: a multicentric study","authors":"Mariana Duarte Azevedo, N. B. de Pinho, Patricia de Carvalho Padilha, Livia Costa de Oliveira, Wilza Arantes Ferreira Peres","doi":"10.3332/ecancer.2024.1662","DOIUrl":"https://doi.org/10.3332/ecancer.2024.1662","url":null,"abstract":"Nutritional screening and assessment are considered essential steps in nutritional care for cancer patients, malnutrition remains underreported in clinical practice. The aim of this study was to analyse the clinical usefulness of the Patient-Generated Subjective Global Assessment short form (PG-SGA SF © ) for nutritional screening in patients with head and neck cancer (HNC). This is a multicentre, cross-sectional study involving patients with HNC. The final score of the PG-SGA SF © was obtained and the nutritional status was diagnosed using the Patient-Generated Subjective Global Assessment (PG-SGA) ® , classifying them as well-nourished or malnourished. Receiver operating characteristic curve, ordinal logistic regression, and C-statistic were used. In total, 353 patients with HNC were enrolled and the prevalence of malnutrition, according to the PG-SGA ® , was 64.02% and the median final score of PG-SGA SF © was 11 points. The final score of the PG-SGA SF © had high accuracy (area under the curve = 0.915), and scores ≥9 had the best performance in diagnosing malnutrition. PG-SGA SF © final score ≥9 was associated with malnutrition (odds ratio = 28.32, 95% confidence interval= 15.98–50.17), with excellent discriminatory power (C-statistic = 0.872). In conclusion, the PG-SGA SF © demonstrated excellent performance for nutritional screening in patients with HNC. Given that it is a simple instrument that is faster to administer than the PG-SGA ® , we recommend its use in clinical practice among such patients.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"17 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139822885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sociodemographic and treatment-related correlates of fatigue in breast cancer survivors at an oncology clinic in Nigeria 尼日利亚一家肿瘤诊所乳腺癌幸存者疲劳的社会人口学和治疗相关关联因素

ecancermedicalscience Pub Date : 2024-01-26 DOI: 10.3332/ecancer.2024.1659

S. Folorunso, Abbas Abdus-Salam, A. Ntekim, Afolabi Adebayo Oladeji, M. Jimoh, Aminat Omolara Folorunso

{"title":"Sociodemographic and treatment-related correlates of fatigue in breast cancer survivors at an oncology clinic in Nigeria","authors":"S. Folorunso, Abbas Abdus-Salam, A. Ntekim, Afolabi Adebayo Oladeji, M. Jimoh, Aminat Omolara Folorunso","doi":"10.3332/ecancer.2024.1659","DOIUrl":"https://doi.org/10.3332/ecancer.2024.1659","url":null,"abstract":"Background: Breast cancer survivors (BCS) still experience fatigue that may impair their quality of life even after completion of treatment. There is a need to understand the sociodemographic and treatment-related factors associated with this to develop relevant and effective interventions. Aim: To assess the relationship between cancer-related fatigue and sociodemographic and treatment-related factors in BCS. Materials and methods: This is a cross-sectional study involving 80 BCS attending the radiation oncology University College Hospital Ibadan. Their sociodemographic, disease and treatment characteristics were obtained. Fatigue Symptom Inventory was used to assess fatigue. A score of at least 3 on average fatigue severity item was taken as cut-off for clinically meaningful fatigue. Result: The mean age of patients was 51.5 years. The prevalence of fatigue was 22.5%. On univariate analysis, fatigue was significantly associated with younger age ( p = 0.022), employment ( p = 0.006), stage of the disease( p = 0.014), anthracycline-based chemotherapy ( p = 0.026), last chemotherapy less than 1 year ( p = 0.001). Using logistic regression analysis, stage (Odds ratio (OR) 5.115, 95% CI 1.029–25.438, p = 0.046), employment status (OR 52.224, 95% CI 3.611–755.899, p = 0.004) and year of last cycle chemotherapy (OR 6.375, 95% CI 1.108–36.680, p = 0.038) were associated with fatigue in BCS. Conclusion: About a quarter of BCS reported fatigue. Advance stage disease, employment status and receiving last course of chemotherapy less than a year are correlates of fatigue.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"31 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139595288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing the law to advance equitable cancer care in South Africa: exploring the feasibility, desirability and added value of a dedicated national cancer act 利用法律促进南非癌症治疗的公平性：探讨专门的国家癌症法案的可行性、可取性和附加值

ecancermedicalscience Pub Date : 2024-01-24 DOI: 10.3332/ecancer.2024.1658

Salomé Meyer, Jane Harries, Julie Torode, Laurel Baldwin-Ragaven

引用次数: 0

ecancermedicalscience Pub Date : 2024-01-22 DOI: 10.3332/ecancer.2024.1657

Arti Suhag, Kamlesh Kumari Sharma, Surya Kant Tiwari, Poonam Joshi, Sameer Rastogi, Simran Kaur

引用次数: 0

Clinical outcomes of ROS1-positive non-small cell lung cancer with limited access to ROS1-tyrosine kinase inhibitors (TKIs): experience from an Indian tertiary referral centre ROS1-酪氨酸激酶抑制剂（TKIs）使用受限的 ROS1 阳性非小细胞肺癌的临床结果：印度一家三级转诊中心的经验

ecancermedicalscience Pub Date : 2024-01-15 DOI: 10.3332/ecancer.2024.1654

G. Panda, V. Noronha, V. Patil, A. Joshi, N. Menon, Rajiv Kumar, T. Pai, O. Shetty, A. Janu, Nivedita Chakrabarty, N. Purandare, Sayak Dey, K. Prabhash

{"title":"Clinical outcomes of ROS1-positive non-small cell lung cancer with limited access to ROS1-tyrosine kinase inhibitors (TKIs): experience from an Indian tertiary referral centre","authors":"G. Panda, V. Noronha, V. Patil, A. Joshi, N. Menon, Rajiv Kumar, T. Pai, O. Shetty, A. Janu, Nivedita Chakrabarty, N. Purandare, Sayak Dey, K. Prabhash","doi":"10.3332/ecancer.2024.1654","DOIUrl":"https://doi.org/10.3332/ecancer.2024.1654","url":null,"abstract":"Introduction: ROS1 as a driver mutation is observed in approximately 1%–2% of all non-small cell lung cancer (NSCLC). Given its rarity, we share our experience regarding ROS1 - positive NSCLC including the access to ROS1 tyrosine kinase inhibitors (TKIs) in a low-middle income country like India. Methods: It is a retrospective analysis of ROS1 -positive NSCLC patients registered between January 2015 to December 2021 for demographics, treatment patterns and outcomes i.e., overall survival (OS) and progression free survival (PFS). Results: Baseline characteristics were available for 70 patients of 78 patients positive for ROS1 by fluorescent in situ hybridisation. Median age at presentation was 52 years, 39 (55.7%) were males, most (51, 72.86%) were non-smokers and ten patients (14.3%) had poor Eastern Cooperative Oncology Group (ECOG) performance status (PS) i.e., PS >2 at presentation. A total of 67 patients receiving cancer directed therapy were analysed for survival. The first line (1L) therapies included – ROS1 TKIs in 38, chemotherapy in 20, epidermal growth factor receptor TKI in eight and chemotherapy-bevacizumab in one only. ROS1 TKI was provided to 20 patients as part of an assistance programme. The median OS for patients who received ROS1 TKI was not attained (95% CI 37.85–NA), while it was 8.11 (95% CI 6.31–NA) months for those who did not (HR-0.1673). The median PFS for the 1L ROS1 TKI compared to the no-TKI group was 27.07 (95% CI 24.28–NA) months versus 5.78 (95% CI 3.42–12) months (HR: 0.2047). Poor ECOG PS at presentation was the only independent prognosticator for survival. Conclusion: Using ROS1 TKI improves clinical outcomes in all-comers though statistically not significant. To further improve outcomes, future trials should pay special attention to patients with poor PS and find a way to increase the current limited access to TKI.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":" 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139623058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of patients with anal cancer treated with definitive chemoradiation: A single centre experience 肛门癌患者接受确定性化疗的疗效：单个中心的经验

ecancermedicalscience Pub Date : 2024-01-15 DOI: 10.3332/ecancer.2024.1655

Mirza Rameez Samar, Bakhtawar Masood, Nida E Zehra, Tahir Munir, Misbah Younus Soomro, Muhammad Arif Hameed, Insia Ali, Yasmin Abdul Rashid

{"title":"Outcomes of patients with anal cancer treated with definitive chemoradiation: A single centre experience","authors":"Mirza Rameez Samar, Bakhtawar Masood, Nida E Zehra, Tahir Munir, Misbah Younus Soomro, Muhammad Arif Hameed, Insia Ali, Yasmin Abdul Rashid","doi":"10.3332/ecancer.2024.1655","DOIUrl":"https://doi.org/10.3332/ecancer.2024.1655","url":null,"abstract":"Background: Anal cancers are uncommon neoplasms that make up to <1% of all tumours globally. Concurrent chemoradiation remains the standard of care treatment for patients who present with non-metastatic anal squamous cell carcinomas (ASCCs). Methods: We aimed to evaluate the response rate and 2-year survival outcome of the definitive chemoradiation approach in patients with non-metastatic ASCCs of our population. We conducted a cross-sectional review of these patient populations who were treated and then followed after completion of treatment at our institute during the last 10 years. Results: A total of 17 patients were enrolled after fulfillment of the eligibility criteria. The responses were documented in 16 patients through magnetic resonance imaging or computed tomography of the pelvis, done at 3 months of treatment completion. More than 80% of the patients had complete radiological responses. Among the surviving participants, the 2-year disease-free survival rate was found to be more than two-thirds. Approximately 20% of the study participants had disease recurrence during the subsequent clinic visits following treatment completion. Conclusion: This review emphasises the impact of definitive chemo-radiation in achieving radiological and clinical responses in patients with non-metastatic ASCCs. Moreover, to our knowledge, this is the first review to highlight anal cancer’s incidence and characteristics in Pakistan.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":" 44","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139621478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementing precision oncology in Latin America to improve patient outcomes: the status quo and a call to action for key stakeholders and decision-makers 在拉丁美洲实施精准肿瘤学以改善患者预后：现状以及对主要利益相关者和决策者的行动呼吁

ecancermedicalscience Pub Date : 2024-01-08 DOI: 10.3332/ecancer.2024.1653

E. M. Ruiz de Castilla, Maurice Mayrides, Haydée González, Francisco Vidangossy, Tatiana Corbeaux, Nancy Ortiz, Claudia Amaya, Alexandra Nuñez, Diego Fernando Jimbo Jimbo, Adela Ayensa, Mayra Galindo, Karla Ruiz, Juan Manuel Pérez

引用次数: 0

Barriers to optimal management of cancer pain in sub-Saharan Africa: a scoping review 撒哈拉以南非洲癌症疼痛优化管理的障碍：范围界定审查

ecancermedicalscience Pub Date : 2023-12-20 DOI: 10.3332/ecancer.2023.1650

V. O. Magboh, Ogheneochuko Andrew Saba, Rene Krause, Patrice Forget

{"title":"Barriers to optimal management of cancer pain in sub-Saharan Africa: a scoping review","authors":"V. O. Magboh, Ogheneochuko Andrew Saba, Rene Krause, Patrice Forget","doi":"10.3332/ecancer.2023.1650","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1650","url":null,"abstract":"Background: Although cancer is a significant issue in sub-Saharan Africa, and cancer pain is prevalent, there is insufficient data and research on the barriers to cancer pain management. Even in countries where evidence exists, few studies explore the links between these barriers, which makes it difficult to implement system-wide approaches to address them. Methods: The search strategy was developed and conducted on databases including MEDLINE, Embase and Web of Science to identify peer-reviewed studies. Then, these retrieved studies were screened systematically to select papers that had met pre-specified criteria. The barriers were categorised into patient, health professional-and health system-level domains. Then, the quality of the included papers was assessed using the mixed methods appraisal tool. Finally, a narrative synthesis was utilised to summarise the findings. Results: Fourteen relevant articles from 19 sub-Saharan African countries were included in the scoping review. All the studies highlighted barriers to optimal cancer pain management. Healthcare system-related domains had the most frequently reported barriers. Approximately half of the included studies met 100% of the methodological quality criteria in the critical appraisal. Conclusion: Improving pain management for cancer patients in sub-Saharan Africa requires further high-level research evidence on regulatory policies and interventional strategies, especially at the health system level, as most barriers to cancer pain treatment essentially stem from the healthcare system.","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"11 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139169545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of upper limb lymphoedema and diagnostic accuracy of bioimpedance spectroscopy. A comprehensive validation in a Brazilian population 评估上肢淋巴水肿和生物阻抗光谱仪的诊断准确性。在巴西人群中进行全面验证

ecancermedicalscience Pub Date : 2023-12-18 DOI: 10.3332/ecancer.2023.1649

Fabíola C Brandini da Silva Tozzo, A. Sarri, Willian Eduardo Pirola, Uliana Basilio Cardoso da Silva, Marco Antonio de Oliveira, Cristiano de Pádua Souza, R. A. da Costa Vieira

{"title":"Evaluation of upper limb lymphoedema and diagnostic accuracy of bioimpedance spectroscopy. A comprehensive validation in a Brazilian population","authors":"Fabíola C Brandini da Silva Tozzo, A. Sarri, Willian Eduardo Pirola, Uliana Basilio Cardoso da Silva, Marco Antonio de Oliveira, Cristiano de Pádua Souza, R. A. da Costa Vieira","doi":"10.3332/ecancer.2023.1649","DOIUrl":"https://doi.org/10.3332/ecancer.2023.1649","url":null,"abstract":"Lymphoedema is a complication of breast cancer treatment. Its early diagnosis is related to a good prognosis for lymphoedema treatment. The bioimpedance spectroscopy (BIS) evaluates changes in extracellular fluid. The objective of our study was to evaluate the validity, agreement and accuracy of BIS in the diagnosis of breast cancer-related lymph-oedema in a Brazilian population. Methods: This is a prospective, cross-sectional study of a convenience sample of 462 women who underwent surgical treatment for breast cancer (mastectomy or breast-conserving treatment). The validity, agreement and accuracy were performed comparing BIS (lymphoedema index (L-DEX) ≥ 6.5 or 10) with volumetry by water displacement, which is the gold standard for evaluating lymphoedema. Receiver operating characteristic curve was performed. Additionally, other methods like perimetry and indirect volumetry of the upper limbs were compared with water displacement volumetry (direct volumetry)","PeriodicalId":502597,"journal":{"name":"ecancermedicalscience","volume":"143 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139174408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0